The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia ; volume:13 ; number:1 ; day:2 ; month:10 ; year:2013 ; pages:1-6 ; date:12.2013
BMC cancer ; 13, Heft 1 (2.10.2013), 1-6, 12.2013
- Urheber
-
Künkele, Annette
- Beteiligte Personen und Organisationen
-
Grosse-Lordemann, Anja
Schramm, Alexander
Eggert, Angelika
Schulte, Johannes H.
Bachmann, Hagen S.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-452
- URN
-
urn:nbn:de:1111-2016030410810
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Künkele, Annette
- Grosse-Lordemann, Anja
- Schramm, Alexander
- Eggert, Angelika
- Schulte, Johannes H.
- Bachmann, Hagen S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Promoter methylation signatures in relapsed pediatric T-cell acute lymphoblastic leukemia
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia
938, Wagen No 938
De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review
JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL
Viral Bcl2s’ transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
938
A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Promoter methylation signatures in relapsed pediatric T-cell acute lymphoblastic leukemia
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia
938, Wagen No 938
De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review
JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL
Viral Bcl2s’ transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2
938
A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Promoter methylation signatures in relapsed pediatric T-cell acute lymphoblastic leukemia
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia
938, Wagen No 938
De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review
JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL
Viral Bcl2s’ transmembrane domain interact with host Bcl2 proteins to control cellular apoptosis
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2